Quick Answer
Outlook Therapeutics, Inc. reported Earnings Per Share Diluted of $1.79 (loss) per share for the year ending 2025.
- Outlook Therapeutics, Inc. showed an increase of +55.9% in Earnings Per Share Diluted from 2024 to 2025.
- This data is from Outlook Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on December 19, 2025.
- XBRL data for this metric is available from 2016 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 9 years of available data (2016 to 2025), Outlook Therapeutics, Inc.'s Earnings Per Share Diluted has grown by 51.2%.
- Historical annual values: Fiscal year 2025: $1.79 (loss) per share | Fiscal year 2024: $4.06 (loss) per share | Fiscal year 2023: $4.72 (loss) per share | Fiscal year 2022: $0.31 (loss) per share | Fiscal year 2021: $0.35 (loss) per share | Fiscal year 2020: $0.67 (loss) per share | Fiscal year 2018: $1.22 (loss) per share | Fiscal year 2017: $1.80 (loss) per share | Fiscal year 2016: $3.67 (loss) per share.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: